{"id":"cal02","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CDK9, CAL02 decreases the production of pro-inflammatory cytokines, which are involved in the development and progression of various inflammatory diseases. This mechanism of action suggests that CAL02 may be effective in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis or psoriasis.","oneSentence":"CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:08.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT05776004","phase":"PHASE2","title":"Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2023-07-22","conditions":"Pneumonia, Bacterial","enrollment":276},{"nctId":"NCT02583373","phase":"PHASE1","title":"Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae","status":"COMPLETED","sponsor":"Combioxin SA","startDate":"2016-03-21","conditions":"Pneumonia, Pneumococcal Infections","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CAL02","genericName":"CAL02","companyName":"Eagle Pharmaceuticals, Inc.","companyId":"eagle-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines. Used for Treatment of rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}